Methimazole-induced agranulocytosis treated with recombinant human granulocyte colony-stimulating factor (G-CSF).
A 35-year-old female hematology technician with Graves' disease developed agranulocytosis a few days after starting therapy with Tapazole (methimazole). Because of a recent report of use of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with propylthiouracil-induced agranulocytosis, 5 micrograms/kg/day G-CSF was administered and her granulocyte count returned to normal after three doses, on the sixth day after the last dose of methimazole. We conclude that in patients with drug-induced agranulocytosis, the use of G-CSF, in addition to discontinuation of the offending drug, hastens recovery and reduces morbidity.
Magner
J A
JA
Department of Medicine, East Carolina University School of Medicine, Greenville, North Carolina 27858.
Snyder
D K
DK
D000328:Adult; D000380:Agranulocytosis / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D001772:Blood Cell Count; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes / Q000187:drug effects; D006111:Graves Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008713:Methimazole / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D008713:Methimazole